NCT00113048TerminatedPhase 1
A Phase I Study of Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
Genzyme, a Sanofi Company2 sites in 1 country24 target enrollmentStarted: December 1, 2003Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Enrollment
- 24
- Locations
- 2
Study Overview
Brief Summary
This phase I study will involve escalating doses of CAMPATH until the goal dose for the cohort is tolerated. The CAMPATH goal dose will be administered to the patient subcutaneously (SQ) 3 times per week for up to 12 weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with relapsed or refractory hematologic malignancy. The anticipated patient population are patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma or myeloma
- •Patients with a history of a hematologic malignancy that has previously been shown by flow cytometry or immunophenotyping analysis to express CD52
- •Any chemotherapy, major surgery or irradiation must have been completed at least four (4) weeks before enrollment in this study (6 weeks for mitomycin-C or nitrosourea)
- •Patients have recovered from the acute side effects due to prior therapy
- •Life expectancy of > 3 months
- •World Health Organization (WHO) Performance Status 0-2
- •18 years of age or older
- •Adequate organ function as defined in the protocol
Exclusion Criteria
- •Prior therapy with CAMPATH
- •Use of an investigational agent within two (2) weeks prior to study enrollment
- •History of anaphylaxis following exposure to humanized monoclonal antibodies
- •Known human immunodeficiency virus (HIV) positive
- •Prior autologous bone marrow or stem cell transplant if within six (6) months of study entry
- •A history or prior allogenic bone marrow transplant or organ transplant
- •Known, symptomatic central nervous system (CNS) involvement with lymphoma
- •Pregnant or lactating women
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (excluding skin infection, lower urinary tract infection, or oral infection), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Unknown
Phase 1
Study of AMV564 in Subjects With Advanced Solid TumorsLocally Advanced or Metastatic Solid TumorsNCT04128423Amphivena Therapeutics, Inc.65
Recruiting
Phase 1
IKS03 in Patients With Advanced B Cell Non-Hodgkin LymphomasB-cell Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaMantle Cell LymphomaFollicular LymphomaB-cell LymphomaNCT05365659Iksuda Therapeutics Ltd.140
Active, not recruiting
Phase 1
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced TumorsAdvanced Solid TumorsNCT05914376Hangzhou Converd Co., Ltd.24
Recruiting
Phase 1
HX044,FIH Study in Patients with Advanced Solid Tumor MalignanciesAdvanced Solid Tumor MalignanciesNCT06649708Hanx Biopharmaceuticals Pty Ltd100
Completed
Phase 1
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)Marginal Zone LymphomaFollicular LymphomaChronic Lymphocytic LeukemiaDiffuse Large B-cell LymphomaRichter Transformation LymphomaBurkitt LymphomaLymphoplasmacytoid LymphomaT-cell Non-Hodgkin LymphomaAcute Lymphoid LeukemiaWaldenstrom MacroglobulinemiaAcute Myeloid LeukemiaMantle Cell LymphomaNCT03833180VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)91